The Injectable Drug Delivery Market Size was valued at USD 114.44 Billion in 2023 and is projected to grow from USD 124.69 Billion in 2024 to USD 229.21 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.21% during the forecast period (2024 - 2032). These systems are designed to transport medications to the target site, making them more localized and easier to reach than through the circulatory system. Patients who depend on their medications daily prefer modern procedures over traditional injection devices. Due to this, manufacturers have a lucrative potential to create complex, user-friendly, and efficient devices due to the growing need for suitable and efficient medication delivery systems, hence driving the market of injectable drug delivery. These are just a few of the market drivers that are driving the market. 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Haselmeier’s Medmix Drug Delivery (Haselmeier) and AARDEX Group in collaboration with combined Haselmeiers D-Flex Logbook and AARDEX Group Medication Adherence software and Hardware ecosystem to improve self administration of injectable drugs in clinical trials within Germany.
In addition, Jabil Healthcare launched the Qfinity autoinjector platform a cheaper alternative to sustainable drug delivery for subcutaneous (SC) subcutaneously injected drugs in May 2022, which is also less expensive than those on the market that integrate into emerging sustainable drug delivery efforts in the pharmaceutical industry of America.
Additionally, Owen Mumford Pharmaceutical Services stated in February 2022 that its UniSafe 1mL safety device for prefilled syringes had been approved as a combination product in Asia. The regulatory approval has occurred for Europe where this is now available as a combi-product with a drug for the treatment of rheumatoid arthritis.
For example, Takeda's TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) was given by US Food and Drug Administration (FDA). This was done on February 2022, but it applies to all patients from twelve years of age or older who suffer from hereditary angioedema (HAE).
January 2022: Hikma Pharmaceuticals USA Inc., a subsidiary of Hikma Pharmaceuticals, launched Diazepam Injection, USP.
For instance, Innovation Zed announced plans to launch InsulCheck DOSE – an add-on device that turns traditional pen injectors into smart solutions for monitoring disease management regimens – through connected pen injector solutions partner SHL Medical during January 2022. Such market players’ engagement will encourage the market growth in forecast period with respect to development of technologically advanced products.
For instance, a global leader in innovative solutions for injectable medication and healthcare products, West Pharmaceutical Services launched NovaGuardSA Pro Safety System – a single use accessory for prefilled ISO standard 0.5mL staked needle syringes – into Indian market on October 2021.
The conventional vial-and-syringe drug administration method has a significant risk of infections and is prone to dosing and handling errors. Alternatively, as they are a secure and highly efficient method of drug delivery to the body, this can be reduced by utilizing pre-filled syringes and reusable glass syringes. Growing patient knowledge and enthusiasm for an easy-to-use, minimally invasive method of injectable drug delivery is what's driving the market's expansion globally. The development of low-cost systems due to their efficiency, precise delivery, and simplicity is another factor boosting the market for injectable medication delivery. Additionally, it is projected that the booming innovations for creating unique drug delivery methods and the quick development of healthcare infrastructure would increase product sales, assisting in the market's growth throughout the forecast period. Thus, this factor is driving the market CAGR.
Technological advancements have significantly impacted the drug distribution sector. For instance, Lexaria Bioscience announced in March 2020 that it would begin researching its Dehydra Tech drug delivery system to combat COVID-19. The upgrade of OXYCAPT, a multilayer plastic vial and syringe that enables numerous qualities, such as an exceptional oxygen barrier, UV barrier, and others, was also announced by Mitsubishi in October 2019. Therefore, it is anticipated that increasing R&D spending and launching cutting-edge products by competitors will foster the market's expansion. During the forecast period, there will be increased usage of wearable, pen-injector, and needle-free injectors for managing infectious and chronic diseases. Numerous pharmaceutical businesses have started updating their offers by reviewing their packaging and sterilizing providers as a result of COVID-19's impact on public awareness of hygiene and safety. The goal of the combination between Catalent and Bristol-Myers Squibb is to provide sterile product manufacturing and packaging. Customers will likely have access to sterilized goods and packaging as a result of the outbreak. Additionally, SCHOTT and West Pharmaceuticals Services signed a collaboration agreement in November 2019 to make sterile-packed, simple, easy-to-use injectable drug delivery systems available to the public. Thus, it is anticipated that this aspect will accelerate Injectable drug delivery market revenue globally.
There is a high potential for infection and dosage and handling mistakes to occur when using the traditional vial and syringe method of administering drugs. On the other hand, this may be minimized by switching to pre-filled syringes or reusable glass syringes, both of which are a safe and highly effective form of medication administration to the body. Increases in patient education and interest in less-intrusive injection methods are fueling the market's growth throughout the world.
The market for injectable drug administration is growing for a number of reasons, including the advent of low-cost devices that are efficient, accurate, and easy to use. Product sales are expected to rise, contributing to the market's expansion throughout the forecast period, and new developments in healthcare infrastructure and novel approaches to medicine administration are expected to fuel the market's expansion. Because of this, the market's CAGR is rising.
June 2023: Vertiva, an On-Body Delivery System (OBDS) designed to be suitable for a wide range of subcutaneous therapies, was introduced in June 2023 by Stevanato Group, S.p.A., a global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries. The innovative design of Vertiva includes a disposable pod that comes with a pre-filled and pre-loaded 3mL ISO cartridge, as well as a controller that may be used several times. A unique magnetically connected driving mechanism facilitates communication between these two components. The device is flexible enough to allow for the delivery of both small-molecule medicines and biologics.
The market segments of injectable drug delivery, based on devices, includes conventional injection devices, and self-injection devices. The self-injection devices segment held the majority share in 2022 in the Injectable drug delivery market revenue. The market's fastest-growing sector comprises the items that makeup self-injection devices. The employment of these tools makes it easier to manage and control numerous illnesses on a fundamental level. Needles-free injectors allow for the painless delivery of pharmaceutical medications, making this market segment one of the most lucrative.
The Injectable drug delivery market segmentation, based on therapeutics application, includes autoimmune diseases, hormonal disorders and cancer. The hormonal disorders and cancer segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Due to the rising number of cancer cases worldwide and the increased amount of research being done to identify treatments for various types of cancer, the hormonal disorders and cancer segment contributed significantly to the worldwide injectable drug delivery market's revenue. Prostate cancer, breast cancer, rectal cancer, lung and bronchial cancer, non-Hodgkin lymphoma, and other malignancies are among the most prevalent. More than 2.3 million women will receive a breast cancer diagnosis in 2020.
Figure 1: Injectable Drug Delivery Market, by Therapeutics Application, 2022 & 2030 (USD Billion) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The injectable drug delivery market data, based on usage pattern, includes curative pattern, and immunization. The immunization segment dominated the market revenue of injectable drug delivery in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The outbreak of a pandemic has greatly increased the demand for country-wide immunization programs and is expected to continue to grow attributing to the prevalence of infectious diseases.
The injectable drug delivery industry, based on usage site of delivery, includes intramuscular, subcutaneous, intradermal. The intramuscular segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the fact that most common injectable drugs are delivered through intramuscular shots such as upper arm, thigh and buttocks.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Injectable drug delivery market accounted for USD 8.01 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The rise in biologics sales and the rise in demand for self-injection devices are factors in the prevalence of chronic diseases. With the increasing cases of chronic diseases, the rise in disposable income, the rising concern for comfort and safety, and the rising number of partnerships in this market, this sector is expected to experience the largest growth. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organisations in the market.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: INJECTABLE DRUG DELIVERY MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Injectable drug delivery market accounts for the second-largest market share. This region now dominates the market for insulin pens in Europe as a result of increasing research and development in this area. The two German businesses, Emperra GmbH E-Health Technologies and Pendiq Intelligent Diabetes Care, respectively, developed and commercialized the insulin pens ESYSTA and Pendiq. Moreover, UK market of Injectable drug delivery held the largest market share, and the Germany market of Injectable drug delivery was the fastest-growing market in the region.
Asia Pacific Injectable drug delivery Market is expected to grow at the fastest CAGR from 2022 to 2030. It is Since more people are becoming aware of these delivery methods, there are more patients, and ready-to-use injectables are replacing traditional drug administration injectables. Further, the China market of Injectable drug delivery held the largest market share, and the India market of Injectable drug delivery was the fastest-growing market in the region.
Injectable Drug Delivery Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of Injectable drug delivery grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Injectable drug delivery industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the Injectable drug delivery industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Injectable drug delivery industry has provided medicine with some of the most significant benefits. The Injectable drug delivery market major player such as Eisai Co. Ltd, Antares Pharma, AstraZeneca, Becton, Dickinson and Company, Eli Lilly and Company.
With its corporate headquarters in Düsseldorf, Gerresheimer AG is a German manufacturer of packaging materials for medication and drug delivery systems manufactured of special-purpose glass and plastics. The corporation operates production facilities in Asia, the Americas, and Europe. Gerresheimer increased the scope of its collaboration with Taisei Medical Co. Ltd. in 2016 to promote its ClearJect syringes and offer technical support to customers. Additionally, the business intends to expand its line of COP syringes in collaboration with Taisei Medical by producing Gx RTF ClearJect brand syringes that combine ClearJect and its glass RTF (ready-to-fill) idea. This partnership is intended to assist the company in expanding both its clientele and product line in the syringe needles sector.
An American international healthcare corporation, Baxter International Inc., has its corporate headquarters in Deerfield, Illinois. The company's main areas of concentration include chronic and acute medical disorders, including kidney illness. The leading manufacturer of active pharmaceutical ingredients, ScinoPharm Taiwan, Ltd., and Baxter International Inc. partnered strategically in February 2017. (API). Five injectable medications will need to be developed, produced, and made available for sale as part of this collaboration.
Key Companies in the market of Injectable drug delivery includes
• Antares Pharma
• AstraZeneca
• Becton
• Dickinson and Company
• Hoffmann-La Roche AG
• Johnson & Johnson Services Inc.
• Mylan N.V.
• Novartis AG
Injectable Drug Delivery Industry Developments
March 2020: In 50-subject human clinical research for their investigational device, the BD Libertas Wearable Injector, Becton, Dickinson, and Company reported that they had completed their purchases.
April 2020: The AJOVY auto-injector has been made available in the United States, according to TEVA Pharmaceuticals USA, Inc. As a prophylactic precaution, this gadget is made to cure adult migraines.
January 2023: The extended-release injectable suspension form of Rykindo® (risperidone) was authorized by the FDA in January 2023. It is prescribed for people with bipolar I disorder as monotherapy or as supplementary therapy to lithium or valproate, and as a biweekly treatment for schizophrenia. Luye Pharmaceutical has created the atypical antipsychotic Rykindo®. The drug's active component, risperidone, is delivered using long-acting and extended-release microsphere technology and is administered via intramuscular injection. As a result, this population now has a promising therapeutic option thanks to the approval of the biweekly extended-release injectable.
February 2023: With the launch of its first product, West Ready Pack with Corning Valor RTU Vials utilizing SG EZ-fill technology, West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announces the expansion of its landmark collaboration with Corning Incorporated. The combination of Valor® RTU Vials with SG EZ-fill® technology results in improved drug storage and delivery, increased availability of critically important public health medications, and increased productivity. Injectable drug storage and distribution are both improved by this strategic partnership by two industry leaders, elastomer and glass system manufacturers. West and Corning are teaming up to create innovative packaging and delivery systems.
Conventional Injection Devices
Self-Injection Devices
Hormonal Disorders and Cancer
Curative pattern
Immunization
Intramuscular
Subcutaneous
Intra Dermal
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 114.44 Billion |
| Market Size 2024 | USD 124.69 Billion |
| Market Size 2032 | USD 229.21 Billion |
| Compound Annual Growth Rate (CAGR) | 7.21% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019 - 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Devices, Therapeutic Application, Site of Delivery and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Eisai Co. Ltd, Antares Pharma, AstraZeneca, Becton, Dickinson and Company, Eli Lilly and Company. |
| Key Market Opportunities | Growing awareness of vaccination in third-world countries |
| Key Market Dynamics | Rapid increase in demand of medical equipment. |
Injectable Drug Delivery Devices Market Highlights:
Frequently Asked Questions (FAQ) :
Market Research Future predicts that Global Injectable Drug Delivery Devices Market is estimated to reach USD 229.21 Billion by 2032
Eisai Co., Ltd, Antares Pharma, AstraZeneca, Becton, Dickinson and Company, Eli Lilly and Company, F. Hoffmann-La Roche AG
Global Injectable Drug Delivery Devices Market is expected to register a CAGR of 7.21% during forecast period upto 2032
Major factor contributing to the growth of the global Injectable Drug Delivery Devices Market is adoption of self-injectable devices, Rising FDA approvals for the drug delivery devices, and others.
The Americas is anticipated to dominate the global Injectable Drug Delivery Devices Market. This region is expected to reach USD 229.21 Billion by 2032 with a CAGR of 7.21% from 2024 to 2032.
The intramuscular had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
